Verrica Pharmaceuticals (NASDAQ:VRCA) announces
positive data from three abstracts evaluating the efficacy and safety
of VP-102 (cantharidin 0.7% Topical Solution) for the treatment of
molluscum contagiosum and common warts.
Pooled analyses of the Phase 3 CAMP studies in
molluscum contagiosum showed VP-102 achieved statistically significantly
higher rate of complete lesion clearance and percentage of subjects
with > 75% and > 90% lesion clearance rates over the course of
therapy compared to vehicle.
VP-102 achieved positive results in the COVE-1
study on the endpoint of complete clearance of all common warts at Day
84 (primary endpoint) as well as Day 147 (exploratory endpoint).
https://seekingalpha.com/news/3506864-verrica-pharma-reports-positive-data-vpminus-102-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.